ClinicalTrials.gg
CompletedNCT03092102Updated Jul 27, 2020

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

A Phase 1 interventional study of HEC585 in Idiopathic Pulmonary Fibrosis, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-27.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
62nd of 188
136 · median 61
Started
2017
with 10 others
Phase 1
39 of 236
3 open now
Registered
112th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 62nd largest by enrollment of the 188 interventional ones that give a count, is one of 11 that started in 2017, is one of 39 in phase 1, and was the 112th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects

Read the detailed description

This will be a double-blind, placebo-controlled, single, and multiple oral dose study conducted in 2 parts.

Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Up to 48 subjects will be studied in up to 6 groups (Groups A1 to A6), with each group consisting of 8 subjects. Each subject will participate in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours postdose), except for Group A3, which will participate in a second treatment period for a food effect evaluation. Each subject in Group A3 will participate in 2 treatment periods separated by a minimum of 7 days. Dosing of subjects in the fed state in Group A3 can commence after review of the safety data from Group A4.

Part B will comprise a multiple-dose, sequential-group study. Up to 36 subjects will be studied in up to 3 groups (Groups B1 to B3), with each group consisting of 12 subjects. Part B of the study may start after completion of Group A5, at a dose equal or less than given in Groups A1 to A3.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, of any race, between 18 and 60 years of age, inclusive, at Screening.
  2. between 18.0 and 32.0 kg/m2, inclusive, at Screening.
  3. In good health, determined by no findings from medical history, physical examination, 12-lead , vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is not acceptable) at Screening and/or Check-in as assessed by the Investigator (or designee).
  4. Females will be nonpregnant and nonlactating. Females of and male subjects will agree to use .
  5. Able to comprehend and willing to sign an form (ICF) and to abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  2. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).
  4. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
  5. Alcohol consumption of > 21 units per week for males and > 14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL wine), or a positive alcohol breath test at Check-in.
  6. Positive urine drugs of abuse screen including cotinine at Screening or Check-in.
  7. Positive surface antigen, virus antibody and/or positive (HIV) test (Appendix 3).
  8. Absolute lymphocyte count below the lower limit of normal which can be confirmed by repeat.
  9. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days or 5 half-lives (if known), whichever is longer, prior to Check-in.
  10. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee). Strong inhibitors and inducers should be avoided.
  11. Use or intend to use any prescription medications/products, within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  12. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  13. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in.
  14. Consumption of foods and beverages containing poppy seeds, grapefruit, or Seville oranges within 7 days prior to Check-in, consumption of caffeine-containing foods and beverages within 72 hours prior to Check-in, or consumption of alcohol within 48 hours prior to Check-in.
  15. Receipt of blood products within 2 months prior to Check-in.
  16. Donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to Screening, or from 6 weeks prior to Screening.
  17. Poor peripheral venous access.
  18. Have previously completed or withdrawn from this study, and have previously received the investigational product.
  19. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    A single dose HEC585(A1)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    A single dose HEC585(A2)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    A single dose HEC585/FE(A3)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule Treatment Period 1:No food prior to dosing;Treatment Period 2:High-fat meal prior to dosing

    Drug: HEC585

  • Experimental
    A single dose HEC585(A4)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    A single dose HEC585(A5)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    A single dose HEC585(A6)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    A single dose HEC585(A7)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    A single dose HEC585(A8)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    Multiple doses HEC585(B1)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    Multiple doses HEC585(B2)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    Multiple doses HEC585(B3)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    Multiple doses HEC585(B4)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    Multiple doses HEC585(B5)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

  • Experimental
    Multiple doses HEC585(B6)

    Drug: HEC585 Capsule Drug: HEC585-matching placebo Capsule

    Drug: HEC585

Interventions

  • DrugHEC585

    HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

06

What researchers measure

Primary outcomes

  1. Cmax

    Geometric Mean of Maximum Observed Plasma Concentration of HEC585

    Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h

  2. (AUC0-∞)

    area under the plasma concentration-time curve (AUC) from time zero to infinity

    Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120,144,and 216 h

  3. tmax

    time of the maximum observed plasma concentration

    Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h

  4. Vz/F

    apparent volume of distribution

    Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120,144,and 216 h

  5. t½

    apparent terminal elimination half-life

    Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h

  6. CL/F

    apparent oral clearance

    Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h

Secondary outcomes

  1. Adverse event

    To assess the safety and tolerability of 7 days therapy.

    Time frame: From baseline to 7 days

07

Study locations

1 site
  • Covance Clinical Research Unit, Inc.
    Madison, Wisconsin 35756, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Feb 2019, 21 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 21 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2017
First posted
Mar 27, 2017
StartActual
May 20, 2017
Primary completionActual
Feb 25, 2019
CompletionActual
Feb 25, 2019
Last update
Jul 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03092102
Responsible party
Sponsor
First posted
Mar 27, 2017
Start date
May 20, 2017
Primary completion
Feb 25, 2019
Completion
Feb 25, 2019
Last update
Jul 27, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yinfenidone

Start the discussion